These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 10522040

  • 1. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy.
    Inoue M, Ohhira M, Ohtake T, Matsumoto A, Kawashima T, Fujimoto Y, Hasebe C, Ono M, Kohgo Y.
    Hepatogastroenterology; 1999; 46(28):2554-60. PubMed ID: 10522040
    [Abstract] [Full Text] [Related]

  • 2. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K, Sakakibara K, Kano H, Lau JY.
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [Abstract] [Full Text] [Related]

  • 3. A case of the development of two hepatocellular carcinomas and a cholangiocarcinoma with cirrhosis after elimination of serum hepatitis C virus RNA with interferon therapy.
    Nagano K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Ebata M, Morita K, Yokozaki S, Takeuchi M, Hayashi K, Takeda S, Nonami T, Hayakawa T.
    Hepatogastroenterology; 2000 Oct; 47(35):1436-8. PubMed ID: 11100370
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.
    Tamori A, Nishiguchi S, Shiomi S, Hayashi T, Kobayashi S, Habu D, Takeda T, Seki S, Hirohashi K, Tanaka H, Kubo S.
    Am J Gastroenterol; 2005 Aug; 100(8):1748-53. PubMed ID: 16086711
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
    Kubo S, Nishiguchi S, Tamori A, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Kuroki T, Kinoshita H.
    Hepatogastroenterology; 2000 Aug; 47(34):1100-2. PubMed ID: 11020887
    [Abstract] [Full Text] [Related]

  • 8. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K.
    Oncol Rep; 1998 Aug; 5(1):205-8. PubMed ID: 9458323
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [Abstract] [Full Text] [Related]

  • 11. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):209-15. PubMed ID: 16091058
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T.
    Cancer; 2004 Oct 01; 101(7):1616-22. PubMed ID: 15378504
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
    Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G.
    Cancer; 2006 Mar 15; 106(6):1326-30. PubMed ID: 16453330
    [Abstract] [Full Text] [Related]

  • 16. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
    Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H.
    Hepatology; 2000 Aug 15; 32(2):228-32. PubMed ID: 10915728
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of well-differentiated hepatocellular carcinoma in large adenomatous hyperplasia after long-term follow-up: a case report.
    Midorikawa Y, Ishikawa T, Kubota K, Mori M, Takayama T, Makuuchi M.
    Hepatogastroenterology; 2002 Aug 15; 49(46):1098-101. PubMed ID: 12143212
    [Abstract] [Full Text] [Related]

  • 19. Interferon can block telomere erosion and in rare cases result in hepatocellular carcinoma development with telomeric repeat binding factor 1 overexpression in chronic hepatitis C.
    Igarashi M, Suda T, Hara H, Takimoto M, Nomoto M, Takahashi T, Okoshi S, Kawai H, Mita Y, Waguri N, Aoyagi Y.
    Clin Cancer Res; 2003 Nov 01; 9(14):5264-70. PubMed ID: 14614008
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
    El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N.
    APMIS; 2006 Jun 01; 114(6):420-7. PubMed ID: 16856963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.